oprah winfrey semaglutide shines her star power on weight loss drugs in TV special Semaglutide: Medical Weight Loss Program

While the main substance patent for semaglutide is expected to expire in 2026, other patents, especially those covering specific formulations, uses, and delivery devices, may extend protections into the 2030s, effectively delaying generic entry

Winfrey first revealed that she was using a type of GLP-1 medication in December 2023, but didn't disclose which one

This difference impacts results: With two hormone pathways working together, tirzepatide can deliver a more comprehensive metabolic effect

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

Eli Lilly, Novo Nordisks main competitor for diabetes and weight loss medication, still holds its patent in Canada and theres no imminent patent expiry for its drugs: Mounjaro and Zepbound